Table 3.

Secondary outcomes in Thai children, at age 1, 2, and 5.7 years, by group.

	1 year			2 year			5.7 year
	n	Value	Pa	n	Value	Pa	n	Value	Pa
Sex, male, n (%)
Iodine	92	38 (41)	0.43	115	50 (43)	0.56	77	32 (42)	0.84
Placebo	104	49 (47)		118	55 (47)		80	35 (44)
Ageb, years
Iodine	92	1.0 (0.1)	0.20	114	2.1 (0.2)	0.97	77	5.6 (0.6)	0.36
Placebo	101	1.0 (0.1)		117	2.1 (0.2)		80	5.7 (0.6)
Bodyweight, kg
Iodine	92	9.3 (1.2)	0.94	113	12.3 (2.0)	0.98	77	19.7 (4.6)	0.08
Placebo	101	9.3 (1.2)		116	12.3 (2.0)		80	21.0 (6.2)
Height, cm
Iodine	92	75.0 (3.5)	0.21	114	87.0 (3.6)	0.74	77	112.1 (6.0)	0.32
Placebo	101	74.6 (3.0)		117	86.9 (4.0)		80	113.2 (6.4)
Height-for-age Z score
Iodine	91	−0.1 (1.3)	0.20	114	−0.2 (1.1)	0.69	77	−0.2 (1.0)	0.34
Placebo	100	−0.3 (1.1)		117	−0.3 (1.1)		80	−0.1 (1.0)
Stunting, n (%)
Iodine	91	5 (5)	0.53	114	6 (5)	0.77	77	2 (3)	0.17
Placebo	100	4 (4)		117	7 (6)		80	0 (0)
Urinary iodine concentrationc, μg/L
Iodine	58	239 (136–386)	0.29	82	231 (149–293)	0.62	77	243 (154–350)	0.70
Placebo	64	273 (184–438)		86	223 (160–325)		78	260 (180–311)
Total thyroxine, nmol/L
Iodine	75	58.5 (41.6–80.9)	0.39	103	64.0 (49.3–83.3)	0.42	76	80.0 (70.1–91.0)	0.11
Placebo	86	60.8 (45.4–88.3)		107	62.6 (47.7–79.8)		77	83.3 (69.1–99.7)
Thyroid stimulating hormone, mIU/L
Iodine	75	0.7 (0.6–1.0)	0.11	103	0.8 (0.6–1.0)	0.03	76	0.9 (0.7–1.1)	0.12
Placebo	86	0.8 (0.6–1.0)		107	0.9 (0.6–1.1)		77	0.9 (0.7–1.2)

^aContinuous data were analyzed using linear mixed effect models with non-transformed or transformed dependent variables. Frequencies were analyzed using mixed effect logistic regression. The interaction effect of treatment by time was tested while controlling for household average monthly income, maternal education, child's birthweight, child's age and child's sex.

^bMean (±SD) (all such values).

^cMedian (IQR) (all such values).